NTHI
Neonc Technologies Holdings, Inc.
$4.49
+0.14 (+3.22%)
At close · Jul 8
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have concluded that there is substantial doubt about our ability to continue as a going concern for at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed May 15, 2026
Market Cap
$116.80M
Shares
26,013,136
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.49
Open$4.31
Day$4.27–4.50
52W$3.69–12.99
Avg vol 30d95K
Short int271K · 1.0% float · 2.8d
Short vol82%
Last earningsMay 18, 2026
DataMar 2025–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−7%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
9%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−53%
trailing
YTD return
−46%
this year
Relative strength
−61%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
1 of 27 funds reported for Jun 30 · net +153.9K sh shares
Insider flow
Accumulating
Net +$187.2K over 90 days · 0% sells
Short interest
Rising
1.04% of float · ▲ +0.7% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 1-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
−52%
Y/Y
EPS growth
−364%
Y/Y
Balance sheet
$58.7K
net cash
Quant / Vol
risk profile
Volatility
102%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Sep 30, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
1 of 27 funds reported for Jun 30 · net +153.9K sh shares
Insider flow
Accumulating
Net +$187.2K over 90 days · 0% sells
Short interest
Rising
1.04% of float · ▲ +0.7% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $4 · 9%
52-wk high $13
vs 200-day avg -43%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Normalized cash operating expenses (annualized, approximate) non-GAAP | $24.4M | Q1 2026 | — |
| Normalized cash operating expenses (approximate) non-GAAP | $6.1M | Q1 2026 | — |
| Radiographic remission rate (NEO100) | 24% | Q1 2026 | — |
| Recommended Phase 2 Dose (RP2D) for NEO212 | 610 | Q1 2026 | — |
| Six-month progression-free survival (NEO100) | 44% | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTHI
this stock
Neonc Technologies Holdings, Inc.
|
$116.80M | -45.7% | -51.8% | — | 1.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTHI | -0.9% | +0.0% | -53.1% | -0.9% | -45.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -0.7% | -0.8% | -60.6% | -0.7% | -55.0% |